Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVTR101
- Development stage
- Phase 2
- Lead developer
- Aventi
- Administration
- Oral
01
Overview
AVTR101 is a botanical drug candidate developed by the South Korean biotechnology company Aventi for the treatment of sarcopenia. It is a standardized extract derived from *Schisandra chinensis* (commonly known as Omija). The therapeutic is designed to address age-related muscle loss and functional decline by promoting muscle protein synthesis and improving mitochondrial function. AVTR101 is currently being evaluated in Phase 2 clinical trials to assess its efficacy in improving physical performance and muscle strength in elderly patients with sarcopenia. The drug is administered orally, typically three times daily.
- Other names
- Schisandra chinensis extractOmija extract
Beyond the preview
Go deeper on AVTR101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVTR101.